**Patent Claims**

1. An antibody that specifically binds to human CD19, wherein the antibody comprises
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: ~~20 or 28~~40,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08.

2. The antibody according to claim 1, wherein the antibody is a monoclonal antibody.

3. The antibody according to any one of claims 1 to 2, wherein the antibody is a human, humanized or chimeric antibody.

4. The antibody according to any one of claim 1 to 3, wherein the antibody is an antibody fragment that specifically binds to human CD19.

5. The antibody according to any one of claims 1 to 4, wherein the antibody comprises
(a) a VH sequence having at least 95 % sequence identity to the amino acid sequence of SEQ ID NO: 09 and a VL sequence having at least 95 % sequence identity to the amino acid sequence of SEQ ID NO: 19, or
(b) a VH sequence having at least 95 % sequence identity to the amino acid sequence of SEQ ID NO: 09 and a VL sequence having at least 95 % sequence identity to the amino acid sequence of SEQ ID NO: 27,or
(c) a VH sequence and a VL sequence as in (a) or (b).

6. A pharmaceutical formulation comprising the antibody according to any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

7. The antibody according to any one of claims 1 to 5 for use as a medicament.

8. The antibody according to any one of claims 1 to 5 for use in the treatment of B-cell cancer.

~~9. The antibody according to any one of claims 1 to 5 for use in the depletion of B-cells.~~

~~10~~9. Use of the antibody according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a disease associated with pathologic increase of B-cells selected from the group consisting of an inflammatory disease, an autoimmune disease, rheumatoid arthritis, lupus and psoriasis.

10. Use of the antibody according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of a B-cell cancer.

11. A method for producing an antibody according to any one of claims 1 to 5 comprising

- culturing cells comprising nucleic acids encoding the antibody according to any one of claims 1 to 5,
- recovering the antibody from the cells or the cultivation medium, and
- purifying the antibody,

thereby producing the antibody according to any one of claims 1 to 5.

~~11. The use according to claim 10, wherein the medicament is for the treatment of a B-cell cancer.~~

~~12. The use according to claim 10, wherein the medicament is for the depletion of B-cells.~~

~~13. A method of treating an individual having a B-cell cancer comprising administering to the individual an effective amount of the antibody according to any one of claims 1 to 5.~~

~~14. A method of depleting B-cells in an individual comprising administering to the individual an effective amount of the antibody according to any one of claims 1 to 5 to deplete B-cells.~~